The recognition of the PI3K/AKT/mTOR pathway as a key regulator of hypoxia‐induced EMT and drug resistance in various cancers underscores the importance of targeting this pathway to improve treatment outcomes and overcome therapeutic challenges. The gene discussed is MTOR; the disease is cancer.